Icagen, Pfizer sign CNS deal; collaboration continues
Icagen (developing small-molecule therapeutics that modulate ion channels) and Pfizer will ally in the discovery, development, and commercialization of compounds against three of Icagen's sodium ion channel targets for pain and related CNS disorders such as epilepsy.
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com